|
|
| Nomenclature |
|
Symbol:
|
Tg(H2-Ead)12Lt
|
|
Name:
|
transgene insertion 12, Edward H Leiter
|
|
MGI ID: |
MGI:3052550 |
|
Synonyms: |
Tg(I-Ealphad,line 12)3Lt |
|
Transgene:
|
Tg(H2-Ead)12Lt
Location:
unknown
|
|
Transgene
origin |
|
Strain of Origin:
|
NOD/ShiLt
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The construct contains a complete H2-Ead gene from the BALB/cByJ mouse including flanking sequence. One copy of the transgene integrated into the genome of line 12 whereas four copies are present in line 5. (J:36435)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
|
Notes |
Diabetes incidence in transgenic mice carrying line 12 is greatly reduced (25% of females, 0% of males) where H2-Ea expression on antigen presenting cells is comparable to BALB/cByJ controls. Although the presence of the transgene in both lines 5 and 12 confers protective influence from IDDM pathologies that affect pancreatic beta cells, autoimmune pathologies effecting other tissues (submandibular salivary, thyroid, kidney) are observed. Histologic examination of the pancreas reveals perivascular/periductal infiltration and peri-insulitus.
|
| References |
|
Original: |
J:36435
Hanson MS et al.,
"Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection."
J Immunol 1996 Aug 1;157(3):1279-87
|
|
All: |
1 reference(s)
|
|
Analysis Tools
